The prognostic significance of fragile X mental retardation syndrome-related protein 1 (FXR1) in breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fragile X mental retardation syndrome-related protein 1 (FXR1) is linked to aggressive breast cancer (BC) and poor outcomes in Saudi women. High FXR1 levels indicate a worse prognosis, suggesting it may be a therapeutic target.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Discovery
Background
- Breast cancer (BC) is a heterogeneous disease with rising incidence in Saudi Arabia.
- Evaluating prognostic factors is crucial for personalized BC therapy.
- Fragile X mental retardation syndrome-related protein 1 (FXR1) is a novel oncogenesis biomarker with an unestablished role in BC.
Purpose Of The Study
- To investigate the clinicopathological significance of FXR1 in primary breast cancer (BC) in women.
- To assess FXR1 as a potential prognostic factor for BC.
Main Methods
- Immunohistochemistry was used to determine FXR1 protein levels in 100 BC tissue samples.
- Associations between FXR1 levels and clinicopathological parameters/outcomes were analyzed.
- FXR1 mRNA levels were assessed in public datasets for validation.
Main Results
- High FXR1 protein levels correlated with advanced tumor stages (IIB/IIIC), hormone receptor negativity, and triple-negative BC (TNBC).
- Elevated FXR1 was associated with poor clinical outcomes.
- High FXR1 mRNA levels also linked to hormone receptor negativity and TNBC.
Conclusions
- FXR1 serves as a prognostic factor for poor prognosis in breast cancer (BC).
- Further research is warranted to explore FXR1's role in aggressive BC and its therapeutic potential.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
